G-5758 is an orally available IRE1α inhibitor with potent activity against XBP1s. It demonstrates strong pharmacodynamic effects and is well tolerated in multiple myeloma models, achieving efficacy at high oral doses in preclinical studies. Reagent grade, for research purpose.
Usually ships within 24 hours.